Sirnaomics Receives IND Clearance from the Taiwan Ministry of Health and Welfare for Phase I Clinical Study of RNAi Therapeutic STP705 for Liver Cancer Treatment
Sirnaomics to Present the Latest Developments of Dual-Targeted RNAi Therapeutics based on its Proprietary GalAhead™ Program at the 4th Annual RNA Therapeutic: From Concept to Clinic Symposium
Our Clinical Development Pipeline is focused on discovering and developing innovative drugs for indications
Our mission is to become a fully-integrated international biopharmaceutical company, leveraging our deep experience in RNA therapeutics and novel delivery platform technologies to rapidly discover and develop innovative drugs for indications with significant unmet medical needs in areas such as cancers, skin conditions, fibrosis-related diseases, antiviral and cardiometabolic diseases, and medical aesthetics.